Decoding Cognitive States from Brain fMRIs: The "Most Differentiating Voxels" Way

C. Namballa,Rahul Erai,K. Venkataramani

DOI: https://doi.org/10.1007/978-3-642-28487-8_38

2012-03-19

Abstract:

What problem does this paper attempt to address?

Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review

Oluwaremilekun Tolu-Akinnawo,David N Ray,Tiwalade Awosanya,Chike Nzerue,Henry Okafor

DOI: https://doi.org/10.7759/cureus.66304

2024-08-06

Cureus

Abstract:Hypertension is the most prevalent modifiable risk factor associated with cardiovascular mortality. The World Health Organization (WHO) estimates that hypertension directly or indirectly causes the death of at least nine million people globally every year. The number of people living with hypertension (blood pressure (BP) of ≥140 mmHg systolic or ≥90 mmHg diastolic or on medication) doubled between 1990 and 2019, from 650 million to 1.3 billion. Despite a plethora of antihypertensive drugs widely available, a sizable part of the antihypertensive population stays uncontrolled. The unmet need of controlling BP in this population may be addressed, in part, by developing new drugs and devices/procedures to treat hypertension and its comorbidities. Several device-based approaches have been introduced to lower BP, and most of these strategies aim to modulate autonomic nervous system activity. Importantly, when considering a device-based treatment, each patient's underlying pathophysiology is considered, and the procedural risks are weighed against the cardiovascular risk attributed to the elevated BP. In November 2023, the FDA approved two renal denervation (RDN) devices. This manuscript discusses current interventional devices and procedures recently approved (RDN) and others in the clinical testing stage for arterial hypertension intervention or management. As we list below, all others have shown promising results and are being evaluated on a larger clinical trial. The new device-based classes are as follows: catheter-based RDN, baroreflex amplification, arteriovenous (AV) malformation, carotid body (CB) ablation, pacemaker-based cardiac neuromodulation, electro-acupuncture, and deep brain stimulation. Baroreflex amplification uses peripheral neuromodulation, while AV malformation leverages AV anastomosis. CB ablation modulates chemoreceptors, and pacemaker-based neuromodulation adjusts atrioventricular intervals. Electro-acupuncture proves potential, and deep brain stimulation offers central nervous system intervention.
The role of renal denervation in cardiology and beyond: An updated comprehensive review and future directives

Aman Goyal,Hritvik Jain,Amogh Verma,Jyoti Jain,Urooj Shamim,Sai Gautham Kanagala,Jatin Motwani,Rohit Chandra Dey,Zainali Chunawala,Amir H Sohail,Agastya D Belur

DOI: https://doi.org/10.1016/j.cpcardiol.2023.102196

Abstract:Renal denervation (RDN) is a minimally invasive intervention performed by denervation of the nervous fibers in the renal plexus, which decreases sympathetic activity. These sympathetic nerves influence various physiological functions that regulate blood pressure (BP), including intravascular volume, electrolyte composition, and vascular tone. Although proven effective in some trials, controversial trials, such as the Controlled Trial of Renal Denervation for Resistant Hypertension (SYMPLICITY-HTN3), have demonstrated contradictory results for the effectiveness of RDN in resistant hypertension (HTN). In the treatment of HTN, individuals with primary HTN are expected to experience greater benefits compared to those with secondary HTN due to the diverse underlying causes of secondary HTN. Beyond its application for HTN, RDN has also found utility in addressing cardiac arrhythmias, such as atrial fibrillation, and managing cases of heart failure. Non-cardiogenic applications of RDN include reducing the intensity of obstructive sleep apnea (OSA), overcoming insulin resistance, and in chronic kidney disease (CKD) patients. This article aims to provide a comprehensive review of RDN and its uses in cardiology and beyond, along with providing future directions and perspectives.
A power resolution for nonsinusoidal and unbalanced systems — Part II: Theoretical background

M. Balci,M. H. Hocaoğlu

2011-12-01

Abstract:It is seen from the study [1] that there is a need for a power resolution, which can be utilized for the direct provision of the optimum compensation capacitor's power and give some useful information on the detection of the harmonic producing loads, in the literature. Accordingly, for nosinusoidal and unbalanced systems, a power resolution, which achieves these goals, is proposed in this paper.
Pitfalls in the radiological diagnosis of malrotation.

S. Beasley,J. D. de Campo

DOI: https://doi.org/10.1111/J.1440-1673.1987.TB01854.X

1987-11-01

Australasian Radiology

Abstract:
Lipschitz Continuity of the Optimal Value via Bounds on the Optimal Set in Linear Semi-Infinite Optimization

M. J. Cánovas,M. López,J. Parra,F. J. Toledo-Moreo

DOI: https://doi.org/10.1287/moor.1060.0198

IF: 2.215

2006-08-01

Mathematics of Operations Research

Abstract:We consider the parametric space of all the linear semi-infinite programming problems with constraint systems having the same index set. Under a certain regularity condition, the so-called well-posedness with respect to the solvability, it is known from Canovas et al. [2] that the optimal value function is Lipschitz continuous around the nominal problem π. In this paper we obtain an explicit Lipschitz constant for such a function in a certain neighborhood of π. We emphasize the fact that both the constant and the size of the neighborhood are exclusively expressed in terms of the nominal problem data, and that they involve the distances to primal and to dual inconsistency. Moreover, a uniform bound for the optimal set is provided. This bound constitutes a key ingredient to derive the Lipschitz constant for the optimal value function.
Renal Denervation in the Management of Resistant Hypertension: A Comprehensive Review of Literature

Salman Salehin,Barbara Karnkowska,Izhan Hamza,Hamza Malik,Daaniya Syeda,Syed Mustajab Hasan,Umamahesh Rangasetty,Syed Gilani,Hani Jneid,Muhammad Raja

DOI: https://doi.org/10.1016/j.cpcardiol.2023.102137

Abstract:Resistant hypertension is a condition in which blood pressure remains elevated despite using 3 or more antihypertensive medications. Though contemporary antihypertensive drug therapies have been essential in treating hypertension, in recent years different studies have explored renal denervation (RDN) as an adjunctive or a replacement modality. Here we summarize an open-label, Symplicity HTN 2 trial and 7 randomized, sham-controlled clinical trials: Spyral-HTN OFF MEDS (Spyral Pivotal), Spyral-HTN ON MEDS, RADIANCE-HTN SOLO, RADIANCE-HTN TRIO, RADIANCE II, SYMPLICITY-HTN 1, and SYMPLICITY-HTN 3, which evaluated safety and efficacy of multiple renal denervation systems (RDN) at lowering blood pressure from baseline, and in comparison, to control group. Prior systematic reviews and meta-analyses evinced a modest reduction of ambulatory and office blood; however, these trials and analyses were limited by short-term follow-up. In our updated comprehensive literature review we summarize the short-term, and long-term effects of RDN, based on the latest randomized clinical trials. Our conclusions based on each summary are unanimous with previous literature findings.
Phytophthora database 2.0: update and future direction.

Bongsoo Park,F. Martin,D. Geiser,Hye-Seon Kim,M. Mansfield,E. Nikolaeva,Sook-Young Park,M. Coffey,Joseph L. Russo,Seong H Kim,Y. Balci,G. Abad,T. Burgess,N. Grünwald,Kyeong-Chae Cheong

DOI: https://doi.org/10.1094/PHYTO-01-13-0023-R

2013-11-12

Phytopathology

Abstract:The online community resource Phytophthora database (PD) was developed to support accurate and rapid identification of Phytophthora and to help characterize and catalog the diversity and evolutionary relationships within the genus. Since its release in 2008, the sequence database has grown to cover 1 to 12 loci for ≈2,600 isolates (representing 138 described and provisional species). Sequences of multiple mitochondrial loci were added to complement nuclear loci-based phylogenetic analyses and diagnostic tool development. Key characteristics of most newly described and provisional species have been summarized. Other additions to improve the PD functionality include: (i) geographic information system tools that enable users to visualize the geographic origins of chosen isolates on a global-scale map, (ii) a tool for comparing genetic similarity between isolates via microsatellite markers to support population genetic studies, (iii) a comprehensive review of molecular diagnostics tools and relevant references, (iv) sequence alignments used to develop polymerase chain reaction-based diagnostics tools to support their utilization and new diagnostic tool development, and (v) an online community forum for sharing and preserving experience and knowledge accumulated in the global Phytophthora community. Here we present how these improvements can support users and discuss the PD's future direction.
Interventional procedures and future drug therapy for hypertension

Melvin D. Lobo,Paul A. Sobotka,Atul Pathak

DOI: https://doi.org/10.1093/eurheartj/ehw303

IF: 39.3

2016-07-11

European Heart Journal

Abstract:Hypertension management poses a major challenge to clinicians globally once non-drug (lifestyle) measures have failed to control blood pressure (BP). Although drug treatment strategies to lower BP are well described, poor control rates of hypertension, even in the first world, suggest that more needs to be done to surmount the problem. A major issue is non-adherence to antihypertensive drugs, which is caused in part by drug intolerance due to side effects. More effective antihypertensive drugs are therefore required which have excellent tolerability and safety profiles in addition to being efficacious. For those patients who either do not tolerate or wish to take medication for hypertension or in whom BP control is not attained despite multiple antihypertensives, a novel class of interventional procedures to manage hypertension has emerged. While most of these target various aspects of the sympathetic nervous system regulation of BP, an additional procedure is now available, which addresses mechanical aspects of the circulation. Most of these new devices are supported by early and encouraging evidence for both safety and efficacy, although it is clear that more rigorous randomized controlled trial data will be essential before any of the technologies can be adopted as a standard of care.

cardiac & cardiovascular systems
Renal denervation – not an easy road to treatment of arterial hypertension and concomitant diseases

Jacek Kądziela

DOI: https://doi.org/10.5604/01.3001.0014.4646

2020-10-21

In a good rythm

Abstract:Percutaneous renal denervation (RDN) has been introduced in clinical trials as the possible interventional method of treatment of resistant hypertension more than one decade ago. The results of trials: SYMPLICITY HTN-1 (single-arm), HTN-2 (randomized, single-blinded) and HTN-3 (with sham procedure) are summarized in this article. The author presents the results of second-generation trials with new technologies: Spyral catheter (radiofrequency RDN) and Paradise system (ultrasound RDN). The favorable results of these studies justify the revision of the current recommendations, limiting this method only to clinical trials. Also the studies on RDN applied in atrial fibrillation and obstructive sleep apnea – diseases related to sympathetic nervous system activity – are discussed.
Renal sympathetic nerve ablation for the management of resistant hypertension: an update

Alicia A Thorp,Robyn N Larsen,Markus P Schlaich

DOI: https://doi.org/10.1097/MNH.0b013e328365adb1

Abstract:Purpose of review: The aim is to provide clinicians with a concise update on renal sympathetic nerve ablation in the management of resistant hypertension. The review will specifically discuss the latest clinical trial findings, technological advancements in ablation modalities and expert guidelines for patient eligibility. Novel therapeutic applications beyond blood pressure (BP) control will also be discussed. Recent findings: Follow-up data from the Symplicity Clinical Trials Program provides further evidence for the safety of the procedure and substantiates a sustained reduction in BP in most patients with resistant hypertension. Recently published expert consensus statements recommend that only patients with resistant hypertension should undergo the procedure at this stage. Several alternative treatment modalities for renal denervation have been developed to improve efficacy, procedure time and safety. Initial findings suggest comparable BP reductions amongst technical approaches. Several pilot studies, although predominantly uncontrolled, indicate additional benefits of renal sympathetic nerve ablation on regression of hypertensive end-organ damage, heart failure, cardiac arrhythmias and other disturbances commonly associated with resistant hypertension. Summary: Catheter-based renal nerve ablation is emerging as a well tolerated, effective and cost-effective treatment to control BP in patients with resistant hypertension. Further studies are required to determine the long-term impact of this novel therapeutic option.
Opportunities and Limitations of Renal Denervation: Where Do We Stand?

Beatriz Castillo Rodriguez,Eric A Secemsky,Rajesh V Swaminathan,Dmitriy N Feldman,Markus Schlaich,Yuri Battaglia,Edward Filippone,Chayakrit Krittanawong,Eric A. Secemsky,Rajesh V. Swaminathan,Dmitriy N. Feldman

DOI: https://doi.org/10.1016/j.amjmed.2024.04.006

IF: 5.928

2024-04-08

The American Journal of Medicine

Abstract:Hypertension is a primary contributor to cardiovascular disease, and the leading risk factor for loss of quality adjusted life years. Up to 50% of the cases of hypertension in the US remain uncontrolled. Additionally, 8-18% of the hypertensive population have resistant hypertension, uncontrolled pressure despite three different anti-hypertensive agents. Recently, catheter-based, percutaneous renal denervation emerged as a method for ablating renal sympathetic nerves for difficult to control hypertension. Initial randomized (non-sham) trials and registry analyses showed impressive benefit, but the first sham-controlled randomized controlled trial (RCT) using monopolar radiofrequency ablation showed limited benefit. With refinement of techniques to include multipolar radiofrequency, ultrasound denervation, and direct ethanol injection, RCTs demonstrated significant blood pressure improvement, leading to FDA approval of radiofrequency and ultrasound-based denervation technologies. In this review article, we summarize the major randomized sham-controlled trials and societal guidelines regarding the efficacy and safety of renal artery denervation for the treatment of uncontrolled hypertension.

medicine, general & internal
Expression of Ets-1 angiogenesis-related protein in gastric cancer.

Souichi Tsutsumi,H. Kuwano,T. Asao,K. Nagashima,T. Shimura,E. Mochiki

DOI: https://doi.org/10.1016/S0304-3835(00)00559-0

IF: 9.756

2000-11-10

Cancer Letters

Abstract:
[Resistant hypertension: integrated strategies between pharmacological treatment and renal denervation]

Giovanna Gallo

DOI: https://doi.org/10.1714/3949.39288

Abstract:The achievement of adequate blood pressure (BP) control and the management of resistant hypertension still represent two burning "unmet needs" in the field of cardiovascular diseases, thus originating a continuous search for more efficacious pharmacological and non-pharmacological strategies including radiofrequency and ultrasound renal denervation (RDN). The most recent guidelines recommend a combination therapy of two or more antihypertensive agents, preferably in a single-pill formulation, as first-line strategy to achieve an effective and early BP control also improving adherence to prescribed treatments. In the last few years several sham-controlled trials have confirmed both the BP-lowering efficacy and safety of RDN in a broad range of patients with hypertension, showing a significant reduction of office and ambulatory BP levels without a relevant increase of procedure-related adverse events such as renal artery stenosis and worsening renal function. These results have been recently confirmed by the analyses of 3-year follow-up data. According to these findings, RDN may represent a useful tool in addition to pharmacological treatment with more compelling indications for patients with resistant hypertension, those who are non-adherent or intolerant to multiple antihypertensive drugs or express a preference to undergo RDN. Further studies are necessary to explore the efficacy of RDN on prevention of hypertension-mediated organ damage and reduction of major cardiovascular events.
Assessing the efficacy of renal denervation in patients with resistant arterial hypertension

Ocílio Ribeiro Gonçalves,Francinny Alves Kelly,José Guilherme Maia,Artur de Oliveira Macena Lôbo,Vitor Kendi Tsuchiya Sano,Maria Eduarda Cavalcanti Souza,Francisco Cezar Aquino de Moraes,Nimra Farid,Arlindo Bispo da Silva Júnior,Avelar Alves da Silva

DOI: https://doi.org/10.1007/s00059-024-05268-9

2024-09-12

Herz

Abstract:Background Renal denervation (RDN) is an innovative procedure designed to regulate the renal sympathetic nervous system for the control of arterial hypertension (HTN). RDN has emerged as an alternative for patients with resistant HTN. However, the clinical efficacy of RDN remains incompletely elucidated. Methods PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs) comparing the use of RDN with sham procedure or pharmacological treatment in patients with resistant HTN. Statistical analyses were performed using R Studio 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria). Heterogeneity was examined with the Cochran Q test I 2 statistics. Mean difference (MD) with 95% confidence interval (CI) were pooled across trials. P values of <0.05 were considered statistically significant. The primary outcomes of interest were changes from baseline in systolic blood pressure (SBP), diastolic blood pressure (DBP), and serum creatinine. Results Twenty-one RCTs comprising 3345 patients were included in this meta-analysis, whereby 2004 (59.91%) received renal denervation and 1341 (40.09%) received pharmacological treatment or sham procedure. Follow-up ranged from 2 to 48 months. Compared to control group, RDN significantly reduced SBP (MD −3.53 mm Hg; 95% CI −5.94 to −1.12; p = 0.004; I 2 = 74%) and DBP (MD −1.48 mm Hg; 95% CI −2.56 to −0.40; p = 0.007; I 2 = 51%). Regarding serum creatinine (MD −2.51; 95% CI −7.90 to 2.87; p = 0.36; I 2 = 40%), there was no significant difference between RDN and control groups. Conclusion In this meta-analysis of RCTs of patients with resistant HTN, RDN was associated with a reduction in SBP and DBP compared to sham procedure or pharmacological treatment.

cardiac & cardiovascular systems
Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation

Omar Azzam,Sayeh Heidari Nejad,Revathy Carnagarin,Janis M Nolde,Marcio Galindo-Kiuchi,Markus P Schlaich

DOI: https://doi.org/10.1111/bph.16247

Abstract:Resistant hypertension is associated with an exceedingly high cardiovascular risk and there remains an unmet therapeutic need driven by pathophysiologic pathways unaddressed by guideline-recommended therapy. While spironolactone is widely considered as the preferable fourth-line drug, its broad application is limited by its side effect profile, especially off-target steroid receptor-mediated effects and hyperkalaemia in at-risk subpopulations. Recent landmark trials have reported promising safety and efficacy results for a number of novel compounds targeting relevant pathophysiologic pathways that remain unopposed by contemporary drugs. These include the dual endothelin receptor antagonist, aprocitentan, the aldosterone synthase inhibitor, baxdrostat and the nonsteroidal mineralocorticoid receptor antagonist finerenone. Furthermore, the evidence base for consideration of catheter-based renal denervation as a safe and effective adjunct therapeutic approach across the clinical spectrum of hypertension has been further substantiated. This review will summarise the recently published evidence on novel antihypertensive drugs and renal denervation in the context of resistant hypertension.
ENDOVASCULAR RADIOFREQUENCY RENAL DENERVATION IN DIFFICULT TO TREAT ARTERIAL HYPERTENSION: A SINGLE CENTER EXPERIENCE

Chiara Grasselli,Vincenzo Guiducci,Gianluca Pignatelli,Aurelio Negro,Angelo Ghirarduzzi

DOI: https://doi.org/10.1097/01.hjh.0001020732.35816.d0

IF: 4.9

2024-05-01

Journal of Hypertension

Abstract:Objective: To assess safety and effectiveness of catheter-based renal denervation (RDN) for reduction of blood pressure (BP) in patients with difficult to treat arterial hypertension. Design and method: Thirtyfive patients selected with difficult to treat arterial hypertension, underwent RDN. Secondary forms of hypertension were excluded, and an appropriate renal artery anatomy was confirmed in all patients. Every patient underwent follow-up at 30 days, and then every 12 months, consisting in clinical examination, office BP measurements, ambulatory blood pressure monitoring, and biochemical analysis. At 12 months tansthoracic echocardiography and renal duplex sonography were performed. Results: The median value of systolic clinic BP decreased from 161 mmHg (25th-75th percentiles 158 - 191) at baseline to 144 mmHg (25th-75th percentiles 136 - 153) at follow up (p= 0.012), and the median value of diastolic clinic BP decreased from 102 mmHg (25th-75th percentiles 94 - 122) at baseline to 90 mmHg (25th-75th percentiles 78 - 99) at follow-up (p= 0.012). The number of medications changed from 5 (range 2-8) at baseline to 3.3 (range 0-6) at follow up. A significant decrease of left ventricular mass index from a median of 160 g/m2 (25th-75th percentiles 147 - 151) at baseline to 126 g/m2 (25th-75th percentiles 107 - 151) at follow-up (p= 0.043) was detected. The renal function did not demonstrate significant changes, however plasma renin activity and HOMA index were significantly reduced. No periprocedural or long term complications were observed. Conclusions: Our data confirm that RDN may constitute an effective and safe therapeutic choice for the treatment of difficult to treat hypertension.

peripheral vascular disease
Effects of renal denervation on the incidence and severity of cardiovascular diseases

Kenichi Katsurada,Kazuomi Kario

DOI: https://doi.org/10.1038/s41440-024-01858-6

2024-09-01

Hypertension Research

Abstract:Renal denervation (RDN) is a neuromodulation therapy performed in patients with hypertension using an intraarterial catheter. Recent randomized sham-controlled trials have shown that RDN has significant antihypertensive effects that last for more than 3 years. Based on this evidence, the US Food and Drug Administration has approved two devices, the ultrasound-based ReCor Paradise TM RDN system and the radiofrequency-based Medtronic Symplicity Spyral TM RDN system, as adjunctive therapy for patients with refractory and uncontrolled hypertension. On the other hand, there have been no randomized sham-controlled prospective outcome trials on RDN, and the effects of RDN on cardiovascular events such as myocardial infarction, heart failure, and stroke have not been elucidated. This mini-review summarizes the latest findings focusing on the effects of RDN on organ protection and physiological function and symptoms in both preclinical and clinical studies. Furthermore, the feasibility of using blood pressure as surrogate marker for cardiovascular outcomes is discussed in the context of relevant clinical studies on RDN. A comprehensive understanding of the beneficial effects of RDN on the incidence and severity of cardiovascular diseases with their underlying mechanisms will enhance physicians' ability to incorporate RDN into clinical strategies to prevent cardiovascular events including myocardial infarction, heart failure, and stroke.

peripheral vascular disease
Clinical trial of a humanized monoclonal anti-IL15Rβ (CD122), in HTLV-1 associated myelopathy/ tropical spastic paraparesis (HAM/TSP)

R. Massoud,Yoshimi Enose-Akahata,Giovanna S. Manzano (Brunetto),J. Ohayon,Kaylan Fenton,I. Cortese,T. Waldmann,S. Jacobson

DOI: https://doi.org/10.1186/1742-4690-11-S1-O6

2014-01-07

Retrovirology

Abstract:
Clinical Benefits of Renal Denervation Besides Blood Pressure Reduction

Han Chen,Li Shen,Junbo Ge

DOI: https://doi.org/10.4103/cp.cp_10_18

2018-01-01

Cardiology Plus

Abstract:Hypertension (HTN) is currently one of the most common chronic diseases, among which some cases are poorly controlled and defined as resistant HTN (RH). Through years of exploration, it has been discovered that hyperactivity in the sympathetic nervous system and the renin–angiotensin system (RAS) initiates the development of RH, followed by other chain reactions in inflammation and oxidative injury. Attributed to their shared pathogenesis with communal cytokines and factors, other comorbidities of HTN, usually associated with cardiovascular and metabolic pathophysiology, often occur alongside primary symptoms, namely, atherosclerosis, heart failure, arrhythmia, and glucose metabolic disorder. Renal denervation (RDN) was first introduced as an alternative measure to help alleviate RH. Renal denervation's clinical relevance comes from directly cutting down afferent and efferent renal nerves, resulting in fewer nerve impulses transmitted to central nervous system and peripheral target organs, and less RAS activation, resulting in lower blood pressure. However, the practical effects of RDN have extended beyond lowering blood pressure and and and plays a role in anti-inflammation and antioxidation pathways. In this review, we briefly summarize the possible mechanism and beneficial clinical effect of RDN treatment in atherosclerosis improvement, cardioprotection, and diabetes remission.
Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis

Davor Vukadinović,Lucas Lauder,David E. Kandzari,Deepak L Bhatt,Ajay J. Kirtane,Elazer R. Edelman,Roland Schmieder,Michel Azizi,Michael Bohm,Felix Mahfoud

DOI: https://doi.org/10.1101/2024.06.12.24308869

2024-06-17

Abstract:Background: Several sham-controlled trials have investigated the efficacy and safety of catheter-based renal denervation (RDN) with mixed outcomes. Aim: To perform a comprehensive meta-analysis of all randomized, sham-controlled trials investigating RDN with first- and second-generation devices in hypertension. Methods: We searched MEDLINE and Cochrane Library for eligible trials. Outcomes included both efficacy (24-hour and office systolic [SBP] and diastolic blood pressure [DBP]) and safety (all-cause death, vascular complication, renal artery stenosis >70%, hypertensive crisis) of RDN. We performed a study-level, pairwise, random-effects meta-analysis of the summary data. Results: Ten trials comprising 2,478 patients with hypertension while being either off- or on-treatment were included. Compared with sham, RDN reduced 24-hour and office systolic BP by 4.4 mmHg (95%CI -6.1, -2.7, p<0.00001) and 6.6 mmHg (95%CI -9.7, -3.6, p<0.0001), respectively. The 24-hour and office diastolic BP paralleled these findings (-2.6 mmHg, 95%CI -3.6, -1.5, p<0.00001; -3.5 mmHg, 95%CI -5.4, -1.6, p=0.0003). There was no difference in 24-hour and office SBP reduction between trials with and without concomitant antihypertensive medication (p for interaction 0.62 and 0.73, respectively). There was no relevant difference concerning vascular complications (OR 1.69, 95%CI 0.57-5.0, p=0.34), renal artery stenosis (OR 1.50, 95%CI 0.06-36.97, p=0.80), hypertensive crisis (OR 0.65, 95%CI 0.30-1.38, p=0.26) and all-cause death (OR 1.76, 95%CI 0.34-9.20, p=0.50) between RDN and sham groups. Change of renal function based on eGFR was comparable between groups (p for interaction 0.84). There was significant heterogeneity between trials. Conclusions: RDN safely reduces ambulatory and office SBP/DBP vs. a sham procedure in the presence and absence of antihypertensive medication.

Decoding Cognitive States from Brain fMRIs: The "Most Differentiating Voxels" Way

Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review

The role of renal denervation in cardiology and beyond: An updated comprehensive review and future directives

A power resolution for nonsinusoidal and unbalanced systems — Part II: Theoretical background

Pitfalls in the radiological diagnosis of malrotation.

Lipschitz Continuity of the Optimal Value via Bounds on the Optimal Set in Linear Semi-Infinite Optimization

Renal Denervation in the Management of Resistant Hypertension: A Comprehensive Review of Literature

Phytophthora database 2.0: update and future direction.

Interventional procedures and future drug therapy for hypertension

Renal denervation – not an easy road to treatment of arterial hypertension and concomitant diseases

Renal sympathetic nerve ablation for the management of resistant hypertension: an update

Opportunities and Limitations of Renal Denervation: Where Do We Stand?

Expression of Ets-1 angiogenesis-related protein in gastric cancer.

[Resistant hypertension: integrated strategies between pharmacological treatment and renal denervation]

Assessing the efficacy of renal denervation in patients with resistant arterial hypertension

Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation

ENDOVASCULAR RADIOFREQUENCY RENAL DENERVATION IN DIFFICULT TO TREAT ARTERIAL HYPERTENSION: A SINGLE CENTER EXPERIENCE

Effects of renal denervation on the incidence and severity of cardiovascular diseases

Clinical trial of a humanized monoclonal anti-IL15Rβ (CD122), in HTLV-1 associated myelopathy/ tropical spastic paraparesis (HAM/TSP)

Clinical Benefits of Renal Denervation Besides Blood Pressure Reduction

Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis